NCT04294264View on ClinicalTrials.gov

TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 12, 2019

Primary Completion Date

March 27, 2024

Study Completion Date

March 27, 2026

Conditions
Metastatic Colorectal CarcinomaRecurrent Colon CarcinomaRefractory Colorectal CarcinomaStage IV Colon Cancer AJCC v7Stage IVA Colon Cancer AJCC v7Stage IVB Colon Cancer AJCC v7
Interventions
DRUG

Oxaliplatin

Given IV

DRUG

Trifluridine and Tipiracil Hydrochloride

Given PO

Trial Locations (6)

07202

Trinitas Hospital and Comprehensive Cancer Center, Elizabeth

08701

RWJBarnabas Health - Monmouth Medical Center Southern Campus, Lakewood

07039

Saint Barnabas Medical Center, Livingston

07740

RWJBarnabas Health - Monmouth Medical Center, Long Branch

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

08755

RWJBarnabas Health - Community Medical Center, Toms River

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Rutgers, The State University of New Jersey

OTHER

NCT04294264 - TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer | Biotech Hunter | Biotech Hunter